ClinicalTrials.gg
CompletedNCT03635957MIRROR OLUpdated Jun 26, 2024Results posted

Study of Pegloticase (KRYSTEXXA®) Plus Methotrexate in Patients With Uncontrolled Gout

A Phase 4 interventional study of Pegloticase and Methotrexate (MTX) in Gout, sponsored by Amgen. Completed at 6 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-06-26.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing pegloticase in Gout — 1 open to participants now, 1 under way, 1 of them phase 3. Pegloticase · Gout.

Enrollment
12th of 14
14 · median 93
Started
2018
the only one that year
Phase 4
7 of 14
none open now
Registered
7th of 14
by date
Lead sponsor
8 of 14
Amgen

Among the 14 studies testing pegloticase in Gout, this one is the 12th largest by enrollment, is the only one that started in 2018, is one of 7 in phase 4, and was the 7th registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 14 studies testing pegloticase in Gout is open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About pegloticase

Pegloticase: first FDA approval 2010 (KRYSTEXXA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing pegloticase in Gout, or all of them as a file.
02

Study summary

The overall objective of the study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of the concomitant use of pegloticase with methotrexate (MTX) to enhance the response rate seen with pegloticase alone in adults with uncontrolled gout.

Read the detailed description

The study design will include: 1) up to a 2-week Screening Period (screening should be complete within 2 weeks prior to Week -4), 2) a 4-week MTX Run in Period (Week - 4 through Day 1); 3) a 52-week Pegloticase + IMM (immunomodulator), (Pegloticase + MTX) Period 4) a Safety Follow-up (Phone/Email/Site Visit) and 5) a 3 and 6 month Post Treatment Follow-up.

Study acquired from Horizon in 2024.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • gout
  • uncontrolled gout
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing and able to give .
  2. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the study.
  3. Adult men or women ≥18 to ≤65 years of age.
  4. Women of (including those with an onset of menopause \<2 years prior to screening, non-therapy-induced amenorrhea for \<12 months prior to screening, or not surgically sterile [absence of ovaries and/or uterus]) must have negative serum/urine pregnancy tests during the Screening/(methotrexate) MTX Run in Period; participants must agree to use 2 reliable forms of during the study, one of which is recommended to be hormonal, such as an oral contraceptive. Hormonal contraception must be started ≥1 full cycle prior to Week -4 (start of MTX dosing) and continue for 30 days after the last dose of pegloticase or at least one ovulatory cycle after the last dose of MTX (whichever is the longest duration after the last dose of pegloticase or MTX). Highly effective contraceptive methods (with a failure rate \<1% per year), when used consistently and correctly, include implants, injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence, or vasectomized partner.
  5. Men who are not vasectomized must not impregnant their female partner during the study and for at least 3 months after the last dose of MTX.
  6. Hyperuricemia at the Screening, Week -4, or Week -2 Visit of the Screening/MTX Run in Period, as documented by sUA ≥6 mg/dL.
  7. Uncontrolled gout, defined as meeting the following criteria:

    serum uric acid (sUA) ≥6 mg/dL prior to entry into the pegloticase +IMM Period (any laboratory tests during screening up to and including during the MTX Run in Period) and at least 1 of the following: inability to maintain sUA \<6 mg/dL on other urate-lowering therapy; intolerable side effects associated with current urate-lowering therapy; functionally limiting tophaceous deposits (including those detected clinically or by dual-energy computed tomography [DECT] imaging)

  8. Able to tolerate MTX 15 mg for 4 weeks during the MTX Run-in Period prior to the first dose of pegloticase.

Exclusion criteria

Exclusion Criteria:

  1. Weight >160 kg (352 pounds).
  2. Any serious acute bacterial infection, unless treated and completely resolved with antibiotics at least 2 weeks prior to the Week -4 Visit of the MTX Run-in Period.
  3. Severe chronic or recurrent bacterial infections, such as recurrent pneumonia or chronic bronchiectasis.
  4. Current condition, including current or chronic treatment with systemic immunosuppressive agents, including prednisone >10 mg/day or equivalent dose of other .
  5. History of any transplant surgery requiring maintenance immunosuppressive therapy.
  6. Known history of virus surface antigen positivity or hepatitis B DNA positivity.
  7. Known history of virus RNA positivity.
  8. (HIV) positivity (tested at the Screening Visit).
  9. Glucose-6-phosphate dehydrogenase (G6PD) deficiency (tested at the Screening Visit).
  10. Severe chronic renal impairment ( \<25 mL/min/1.73 m\^2) or currently on dialysis.
  11. Non-compensated congestive heart failure or hospitalization for congestive heart failure within 3 months of the Screening Visit, uncontrolled arrhythmia, treatment for acute coronary syndrome (myocardial infarction or unstable angina), or uncontrolled blood pressure (>160/100 mmHg) at the end of the Screening/MTX Run-in Period.
  12. Pregnant, planning to become pregnant, breastfeeding, planning to impregnant female partner, or not on an effective form of , as determined by the Investigator.
  13. Prior treatment with pegloticase (KRYSTEXXA®), another recombinant uricase (rasburicase), or concomitant therapy with a polyethylene glycol-conjugated drug.
  14. Known allergy to pegylated products or history of anaphylactic reaction to a recombinant protein or porcine product.
  15. to MTX treatment or MTX treatment considered inappropriate.
  16. Known intolerance to MTX.
  17. Receipt of an drug within 4 weeks or 5 half-lives, whichever is longer, prior to MTX administration at Week -4 or plans to take an investigational drug during the study.
  18. Current liver disease, as determined by or aspartate transaminase levels >3 times at the Screening Visit.
  19. Currently receiving systemic or radiologic treatment for ongoing cancer, excluding non melanoma skin cancer.
  20. History of within 5 years other than non-melanoma skin cancer or in situ carcinoma of cervix.
  21. Uncontrolled hyperglycemia with a plasma glucose value >240 mg/dL at screening that is not subsequently controlled by the end of the Screening/MTX Run-in Period.
  22. Diagnosis of osteomyelitis.
  23. Known history of hypoxanthine-guanine phosphoribosyl-transferase deficiency, such as Lesch-Nyhan and Kelley-Seegmiller syndrome.
  24. Unsuitable candidate for the study, based on the opinion of the Investigator (e.g., cognitive impairment), such that participation might create undue risk to the participant or interfere with the participant's ability to comply with the protocol requirements or complete the study.
  25. Alcohol use in excess of 3 alcoholic beverages per week.
  26. Currently receiving allopurinol and unable to discontinue medication 7 days prior to MTX dosing at Week -4 and unable to discontinue treatment during the duration of the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Pegloticase With Methotrexate (MTX)

    Run-In Period: oral MTX at a dose of 15 mg weekly for 4 weeks prior to the first dose of pegloticase. Pegloticase + Immunomodulator (IMM) Period: pegloticase 8 mg administered intravenously (IV) every 2 weeks from Day 1 through the Week 50 Visit for a total of 26 infusions. MTX 15 mg weekly on the same day each week, within 1 to 3 days prior to each pegloticase infusion and one additional weekly dose after the last infusion.

    Biological: Pegloticase · Drug: Methotrexate (MTX) · Drug: Standard Gout Flare Prophylaxis · Drug: Infusion Reaction (IR) Prophylaxis · Dietary Supplement: Folic Acid

Interventions

  • BiologicalPegloticase

    pegloticase administered intravenously (IV)

  • oral MTX

  • DrugStandard Gout Flare Prophylaxis

    It is required that before a subject begins the Pegloticase + IMM Period, he or she has been taking at least one protocol standard gout flare prophylaxis regimen (i.e. colchicine and/or nonsteroidal anti-inflammatory drugs and/or low-dose prednisone ≤10 mg/day) for ≥1 week before the first dose of pegloticase and continues flare prophylaxis per American College of Rheumatology guidelines \[Khanna D et al.2012\] for the greater of 1) 6 months, 2) 3 months after achieving target serum urate (sUA \< 6 mg/dL) for patients with no tophi detected on physical exam, or 3) 6 months after achieving target serum urate (sUA \< 5 mg/dL) for patients with one or more tophi detected on initial physical exam that have since resolved.

  • DrugInfusion Reaction (IR) Prophylaxis

    For IR prophylaxis, fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) will be taken the day before each infusion; fexofenadine (60 mg or 180 mg orally based on the Principal Investigator's discretion) and acetaminophen (1000 mg orally) will be taken the morning of each infusion; and methylprednisolone (125 mg IV) given over the infusion duration 10-30 minutes (recommended) or hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.

  • Dietary supplementFolic Acid

    Subjects will also take folic acid 1 mg orally every day beginning at Week -4 (the start of MTX) and continuing until prior to the Week 52 Visit.

06

What researchers measure

Primary outcomes

  1. Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6

    Serum uric acid (sUA \< 6 mg/dL) responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24.

    Time frame: Month 6 (Weeks 20, 22, and 24)

Secondary outcomes

  1. Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3

    Serum uric acid (sUA \< 6 mg/dL) responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion.

    Time frame: Month 3 (Weeks 10, 12, and 14)

  2. Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders

    Serum uric acid (sUA \< 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is \< 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6.

    Time frame: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

  3. Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3

    Serum uric acid (sUA \< 5 mg/dL) responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion.

    Time frame: Month 3 (Weeks 10, 12, and 14)

  4. Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6

    Serum uric acid (sUA \< 5 mg/dL) responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24.

    Time frame: Month 6 (Weeks 20, 22, and 24)

  5. Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders

    Serum uric acid (sUA \< 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is \< 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6.

    Time frame: Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)

  6. Mean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52

    The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis.

    Time frame: Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52

07

Results

Posted Nov 18, 2020
Limitations and caveats
One participant was dosed with MTX in the Run-In Period (MTX tolerance period) but was lost to follow up prior to the per protocol enrollment at Day 1. This participant was a screen failure but is included in Run-in period data (including safety).

Participant flow

Run-In Period
Participant flow — Run-In Period
MilestoneAll Participants
Started15
Completed14
Not completed1
Withdrew: Lost to follow-up1
Pegloticase + IMM Period
Participant flow — Pegloticase + IMM Period
MilestoneAll Participants
Started14
Completed study at 24 weeks-amendment 11
Completed study at 52 weeks-amendment 210
Discontinued study treatment early5
Had 3-month follow-up7
Had 6-month follow-up6
Completed11
Not completed3
Withdrew: Lack of efficacy3

Outcome measures

PrimaryPercentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6

Serum uric acid (sUA \< 6 mg/dL) responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 6 (Weeks 20, 22, and 24). Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24.

Time frame:
Month 6 (Weeks 20, 22, and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 6
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 678.6 (49.2 to 95.3)
SecondaryPercentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3

Serum uric acid (sUA \< 6 mg/dL) responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 3 (Weeks 10, 12, and 14). Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion.

Time frame:
Month 3 (Weeks 10, 12, and 14)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 3
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Responders During Month 378.6 (49.2 to 95.3)
SecondaryPercentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders

Serum uric acid (sUA \< 6 mg/dL) overall responders are defined as participants achieving and maintaining sUA \< 6 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is \< 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6.

Time frame:
Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 6 mg/dL) Overall Responders78.6 (49.2 to 95.3)
SecondaryPercentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3

Serum uric acid (sUA \< 5 mg/dL) responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 3. Month 3 includes pre-infusion and post-infusion sUA assessments at Week 10, pre-infusion and post-infusion sUA assessments at Week 12, pre-infusion assessments at Week 14, and unscheduled assessments between Week 10 and Week 14 pre-infusion.

Time frame:
Month 3 (Weeks 10, 12, and 14)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 3
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 378.6 (49.2 to 95.3)
SecondaryPercentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6

Serum uric acid (sUA \< 5 mg/dL) responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 6. Month 6 includes pre-infusion and post-infusion sUA assessments at Week 20, pre-infusion and post-infusion sUA assessments at Week 22, pre-infusion assessments at Week 24, and unscheduled sUA assessments between Week 20 and Week 24.

Time frame:
Month 6 (Weeks 20, 22, and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 6
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Responders During Month 678.6 (49.2 to 95.3)
SecondaryPercentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders

Serum uric acid (sUA \< 5 mg/dL) overall responders are defined as participants achieving and maintaining sUA \< 5 mg/dL for at least 80% of the time during Month 3 and Month 6 (Weeks 10, 12, 14, 20, 22, and 24) combined. Participants with more than one sUA result in Month 3 and Month 6 are considered responders if a participant's weighted proportion of hours that sUA is \< 6 mg/dL is greater than or equal to 80%. Participants with the proportion of hours less than 80% are counted as non-responders. Participants with only one value in Month 3 and Month 6 are considered overall responders if they are considered responders in both Month 3 and Month 6.

Time frame:
Month 3 and Month 6 combined (Weeks 10, 12, 14, 20, 22, and 24)
Reported as:
Number · percentage of participants
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders
percentage of participantsPegloticase With Methotrexate (MTX)
Percentage of Serum Uric Acid (sUA < 5 mg/dL) Overall Responders78.6 (49.2 to 95.3)
SecondaryMean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52

The mean change from baseline is based on observed values in participants remaining on treatment at given time point. For sUA values less than the lower limit of detection (up to 1.5 mg/dL), 0 is used in the analysis.

Time frame:
Baseline (defined as the last measurement taken prior to the first infusion of pegloticase in the pegloticase + IMM period), Pre- and Post-Infusion at Weeks 14, 24, 36 and Week 52
Reported as:
Mean · mg/dL
Mean Change in sUA From Pegloticase Baseline to Weeks 14, 24, 36, 52
mg/dLPegloticase With Methotrexate (MTX)
Change at Week 14 - pre-infusion-9.27 ± 2.810
Change at Week 14 - post-infusion-9.31 ± 2.959
Change at Week 24 - pre-infusion-9.27 ± 2.810
Change at Week 24 - post-infusion-9.48 ± 4.135
Change at Week 36 - pre-infusion-8.13 ± 3.975
Change at Week 36 - post-infusion-9.41 ± 3.293
Change at Week 52-8.15 ± 4.086

Adverse events

Collected over From first dose of study drug through the end of treatment plus 30 days. Mean duration of MTX Treatment during the MTX Run-in Period was 23.0 days, and during the Pegloticase+IMM Period was 242.4 days. Mean duration of pegloticase treatment during the Pegloticase + IMM Period was 242.4 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Run-In Period: MTX0/15 (0%)0/15 (0%)10/15 (66.7%)
Pegloticase + IMM Period: Pegloticase + MTX0/14 (0%)1/14 (7.1%)14/14 (100%)
Most frequent serious events
Most frequent serious events
EventRun-In Period: MTXPegloticase + IMM Period: Pegloticase + MTX
Bacterial SepsisInfections and infestations0/151/14
Most frequent other events
Showing 10 of 46
Most frequent other events
EventRun-In Period: MTXPegloticase + IMM Period: Pegloticase + MTX
GoutMetabolism and nutrition disorders5/1513/14
DiarrhoeaGastrointestinal disorders1/153/14
NasopharyngitisInfections and infestations1/153/14
Upper Respiratory Tract InfectionInfections and infestations0/153/14
Muscle StrainInjury, poisoning and procedural complications0/153/14
ArthralgiaMusculoskeletal and connective tissue disorders0/153/14
SinusitisInfections and infestations0/152/14
HypertensionVascular disorders0/152/14
Abdominal DiscomfortGastrointestinal disorders2/150/14
NauseaGastrointestinal disorders2/151/14

Baseline characteristics

Modified intention-to-treat (mITT) population: all enrolled participants who received ≥1 dose of pegloticase.

Age, Continuous
Age, Continuous(years)Pegloticase With Methotrexate (MTX)
Mean49.3 ± 8.66
Sex: Female, Male
Sex: Female, Male(Participants)Pegloticase With Methotrexate (MTX)
Female0
Male14
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pegloticase With Methotrexate (MTX)
Hispanic or Latino1
Not Hispanic or Latino13
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegloticase With Methotrexate (MTX)
American Indian or Alaska Native0
Asian2
Native Hawaiian or Other Pacific Islander0
Black or African American0
White12
More than one race0
Unknown or Not Reported0
Serum Uric Acid (sUA)
Serum Uric Acid (sUA)(mg/dL)Pegloticase With Methotrexate (MTX)
Mean9.16 ± 2.486
08

Study locations

6 sites
  • Orthopedic Physicians Alaska
    Anchorage, Alaska 99508, United States
  • Arizona Arthritis & Rheumatology -West Valley
    Glendale, Arizona 85306, United States
  • Arizona Arthritis & Rheumatology -East Valley
    Mesa, Arizona 85210, United States
  • Avail Clinical Research
    DeLand, Florida 32720, United States
  • Western Washington Arthritis Clinic
    Bothell, Washington 98021, United States
  • Arthritis Northwest PLLC
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, Song Y, LaMoreaux B, Zhao L, Xin Y, Chamberlain J, Ramanathan S, Weinblatt ME, Peterson J. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study. Arthritis Res Ther. 2022 Aug 25;24(1):208. doi: 10.1186/s13075-022-02865-z. PubMed 36008814 ↗
  • Dalbeth N, Becce F, Botson JK, Zhao L, Kumar A. Dual-energy CT assessment of rapid monosodium urate depletion and bone erosion remodelling during pegloticase plus methotrexate co-therapy. Rheumatology (Oxford). 2022 Nov 28;61(12):4898-4904. doi: 10.1093/rheumatology/keac173. PubMed 35293984 ↗
  • Botson JK, Tesser JRP, Bennett R, Kenney HM, Peloso PM, Obermeyer K, LaMoreaux B, Weinblatt ME, Peterson J. Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR). J Rheumatol. 2021 May;48(5):767-774. doi: 10.3899/jrheum.200460. Epub 2020 Sep 15. PubMed 32934137 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2019, 12 months.

Results were first posted in Nov 2020, 1 year after primary completion.

Of 19 phase 4 interventional studies under Gout, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2018
First posted
Aug 17, 2018
StartActual
Sep 26, 2018
Primary completionActual
Oct 23, 2019
CompletionActual
Oct 26, 2020
Results first posted
Nov 18, 2020
Last update
Jun 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03635957
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 17, 2018
Start date
Sep 26, 2018
Primary completion
Oct 23, 2019
Completion
Oct 26, 2020
Results posted
Nov 18, 2020
Last update
Jun 26, 2024

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pegloticase · Methotrexate

Start the discussion